Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 304Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
PHARMACOVIGILANCE PERSPECTIVE
Year : 2018  |  Volume : 9  |  Issue : 2  |  Page : 103-106

Analysis of serious adverse event: Writing a narrative


BHSc (Home Science), Post Graduate Dietetics, Registered Dietician, Mumbai, India

Correspondence Address:
Ms. Indu Nambiar
P. G. Diploma in Dietetics, Registered Dietitian, 1002, Hallmark Business Plaza, Near Guru Nanak Hospital, Near Guru Nanak Hospital Road, Bandra (East), Mumbai - 400 051, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/picr.PICR_52_18

Rights and Permissions

One of the reasons that a research molecule undergoes through different phases of clinical trials is to establish the safety and efficacy of the drug. To establish the safety profile of any drug, the most important aspect is to evaluate every adverse event (AE) that a clinical trial individual experiences. This detail is provided by any investigator or sponsor through the narratives that is prepared post the analysis of a serious AE. The purpose of this article is to emphasize the importance of these narratives.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1590    
    Printed20    
    Emailed0    
    PDF Downloaded233    
    Comments [Add]    

Recommend this journal